title: Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study.
abstract: OBJECTIVE
  This study was aimed to investigate the effects of olmesartan or nebivolol treatment on blood pressure and some endothelial function markers in newly diagnosed patients with stage 1 essential hypertension.
  
  
  METHODS
  This randomized open label study included 85 newly diagnosed patients with stage 1 hypertension (50 males, mean age: 52 ± 9 years). Blood pressure, flow mediated vasodilatation (FMD) and echocardiographic measurements of the patients were taken before and 8 weeks after the beginning of treatment with olmesartan or nebivolol. Nitric oxide, plasminogen activator inhibitor 1 (PAI-1) and C reactive protein (CRP) levels measured in serum samples before and after treatment, were compared. Basal variables that can affect the antihypertensive response were evaluated by multivariate logistic regression analysis.
  
  
  RESULTS
  The reduction observed in the systolic and diastolic blood pressures after antihypertensive treatment was significant (p<0.05). FMD was significantly improved after treatment in both nebivolol and olmesartan groups; however, there was no significant difference between nebivolol and olmesartan groups (p=0.6). While CRP and PAI-1 levels decreased, nitric oxide levels increased in both nebivolol and olmesartan treatment groups; but these changes were not statistically significant. No drug related complication was observed.
  
  
  CONCLUSIONS
  This study has indicated that olmesartan and nebivolol causes similar changes in blood pressure response, FMD and endothelial function biomarkers improved. These results suggest that antihypertensive treatment, independent of the medication used, is associated with endothelial function improvement.
authors.affiliation: Clinic of Medical Oncology, Ankara Numune Training and Research Hospital; Ankara-Turkey. masendur@yahoo.com.tr.
authors.forename: Mehmet Ali Nahit
authors.initials: MA
authors.lastname: Sendur
authors.forename: Gülay Sain
authors.initials: GS
authors.lastname: Güven
authors.forename: Hikmet
authors.initials: H
authors.lastname: Yorgun
authors.forename: Ahmet Hakan
authors.initials: AH
authors.lastname: Ateş
authors.forename: Uğur
authors.initials: U
authors.lastname: Canpolat
authors.forename: Hamza
authors.initials: H
authors.lastname: Sunman
authors.forename: Sevilay
authors.initials: S
authors.lastname: Karahan
authors.forename: Bariş
authors.initials: B
authors.lastname: Kaya
authors.forename: Kudret
authors.initials: K
authors.lastname: Aytemir
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure; D002097:C-Reactive Protein / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol / Q000008:administration & dosage*; D009569:Nitric Oxide / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D014421:Turkey; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D017395:Plasminogen Activator Inhibitor 1; D013777:Tetrazoles; D000068577:Nebivolol; D009569:Nitric Oxide; C437965:olmesartan; D002097:C-Reactive Protein